[1] 杨媛华.《中国肺动脉高压诊断与治疗指南(2021版)》解读——肺动脉高压的诊断[J]. 中国实用内科杂志,2021,41(8):696-699.
[2] KLINGER JR, ELLIOTT CG, LEVINE DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the chest guideline and expert panel report. Chest. 2019;155(3):565-586.
[3] BENJAMIN N, MARRA AM, EICHSTAEDT C, et al. Exercise training and rehabilitation in pulmonary hypertension. Heart Fail Clin. 2018;14(3):425-430.
[4] SANTOS-LOZANO A, FIUZA-LUCES C, FERNÁNDEZ-MORENO D, et al. Exercise benefits in pulmonary hypertension. J Am Coll Cardiol. 2019;73(22):2906-2907.
[5] CASSADY SJ, RAMANI GV. Right heart failure in pulmonary hypertension. Cardiol Clin. 2020;38(2):243-255.
[6] GHIO S, RAINERI C, SCELSI L, et al. Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. Heart Fail Rev. 2020;25(1):85-91.
[7] CHIABRANDO JG, FEOLA M. Exercise and adverse ventricular remodeling: the cornerstone of heart failure. Minerva Cardiol Angiol. 2021;69(4):435-437.
[8] HANDOKO ML, DE MAN FS, HAPPÉ CM, et al. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation. 2009;120(1):42-49.
[9] MEYRICK B, GAMBLE W, REID L. Development of crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol. 1980;239(5):H692-702.
[10] 张艳,何瑞波,王庆博,等.不同负荷量有氧运动对肥胖大鼠骨骼肌炎症反应和胰岛素信号途径的影响及机制[J].中国组织工程研究,2023,27(8):1237-1244.
[11] XU X, CHEN C, LU WJ, et al. Pyrroloquinoline quinone can prevent chronic heart failure by regulating mitochondrial function. Cardiovasc Diagn Ther. 2020;10(3): 453-469.
[12] 张昊,王伟伟,薛过,等.运动训练通过诱导自噬、抑制凋亡改善老龄大鼠心脏功能[J].中国病理生理杂志,2014,30(1):11-17.
[13] 王增喜,李洁,王悦.高强度间歇训练对大鼠心肌线粒体呼吸链复合体活性的影响[J].中国运动医学杂志,2018,37(4):315-322.
[14] BOGAARD HJ, NATARAJAN R, HENDERSON SC, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009; 120(20):1951-1960.
[15] WEISSMANN N, PETERS DM, KLÖPPING C, et al. Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. Am J Physiol Lung Cell Mol Physiol. 2014;306(11):L986-995.
[16] SAEED S, HOLM H, NILSSON PM. Ventricular-arterial coupling: definition, pathophysiology and therapeutic targets in cardiovascular disease. Expert Rev Cardiovasc Ther. 2021;19(8):753-761.
[17] SPRUIJT OA, DE MAN FS, GROEPENHOFF H, et al. The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension. Am J Respir Crit Care Med. 2015;191(9):1050-1057.
[18] EHLKEN N, LICHTBLAU M, KLOSE H, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J. 2016;37(1):35-44.
[19] BLANCO I, TORRES-CASTRO R, BARBERÀ JA. Exercise tolerance in pulmonary hypertension. Arch Bronconeumol. 2022;58(5):388-389.
[20] O’CALLAGHAN DS, HUMBERT M. A critical analysis of survival in pulmonary arterial hypertension. Eur Respir Rev. 2012;21(125):218-222.
[21] GRÜNIG E, MACKENZIE A, PEACOCK AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J. 2021;42(23):2284-2295.
[22] ROIBAL PRAVIO J, BARGE CABALLERO E, BARBEITO CAAMAÑO C, et al. Determinants of maximal oxygen uptake in patients with heart failure. ESC Heart Fail. 2021;8(3):2002-2008.
[23] KASHIMURA O, SAKAI A, YANAGIDAIRA Y. Effects of exercise-training on hypoxia and angiotensin II-induced pulmonary vasoconstrictions. Acta Physiol Scand. 1995;155(3):291-295.
[24] STĘPNOWSKA E, LEWICKA E, DĄBROWSKA-KUGACKA A, et al. Prognostic factors in pulmonary arterial hypertension: Literature review. Adv Clin Exp Med. 2017; 26(3):549-553.
[25] ROGNMO Ø, MOHOLDT T, BAKKEN H, et al. Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation. 2012;126(12):1436-1440.
[26] HUSSAIN SR, MACALUSO A, PEARSON SJ. High-intensity interval training versus moderate-intensity continuous training in the prevention/management of cardiovascular disease. Cardiol Rev. 2016;24(6):273-281.
[27] GONZÁLEZ A, SCHELBERT EB, DÍEZ J, et al. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018; 71(15):1696-1706.
[28] LIAO Z, LI D, CHEN Y, et al. Early moderate exercise benefits myocardial infarction healing via improvement of inflammation and ventricular remodelling in rats. J Cell Mol Med. 2019; 23(12):8328-8342.
[29] 王雪芳,谢萍.肺动脉高压与免疫炎症[J].临床心血管病杂志,2019,35(5): 397-401.
[30] KUMARI R, KUMAR S, AHMAD MK, et al. TNF-α/IL-10 ratio: an independent predictor for coronary artery disease in North Indian population. Diabetes Metab Syndr. 2018; 12(3):221-225.
[31] NOVOYATLEVA T, SCHYMURA Y, JANSSEN W, et al. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol. 2013;108(2):e325.
[32] FALCÃO-PIRES I, GONÇALVES N, HENRIQUES-COELHO T, et al. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;296(6): H2007-2014.
[33] LOURENÇO AP, RONCON-ALBUQUERQUE R JR, BRÁS-SILVA C, et al. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol. 2006;291(4):H1587-1594.
[34] MIAO H, QIU F, ZHU L, et al. Novel angiogenesis strategy to ameliorate pulmonary hypertension. J Thorac Cardiovasc Surg. 2021;161(6):e417-434.
[35] MORKIN E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech. 2000;50(6):522-531.
[36] JAMES J, HOR K, MOGA MA, et al. Effects of myosin heavy chain manipulation in experimental heart failure. J Mol Cell Cardiol. 2010;48(5):999-1006.
[37] KORTE FS, HERRON TJ, ROVETTO MJ, et al. Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am J Physiol Heart Circ Physiol. 2005;289(2):H801-812.
[38] ZHIHAO L, JINGYU N, LAN L, et al. SERCA2a: a key protein in the Ca2+ cycle of the heart failure. Heart Fail Rev. 2020;25(3):523-535.
[39] HSU CH, ROAN JN, FANG SY, et al. Transplantation of viable mitochondria improves right ventricular performance and pulmonary artery remodeling in rats with pulmonary arterial hypertension. J Thorac Cardiovasc Surg. 2022;163(5):e361-373.
[40] PEOPLES JN, SARAF A, GHAZAL N, et al. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med. 2019;51(12):1-13.
[41] JIANG M, ZHAO XM, JIANG ZS, et al. Protein tyrosine nitration in atherosclerotic endothelial dysfunction. Clin Chim Acta. 2022;529:34-41.
|